ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.
This video was recorded during the ESC Congress 2020.
Prof. Hiddo Heerspink, PhD is a clinical pharmacologist at the University Medical Center Groningen (UMCG) in the Netherlands
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- ESC 2020No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
Prof. Freek Verheugt, MD
Milton Packer, MD
Prof. Isabelle van Gelder, MD
Kazem Rahimi, MD